Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons - PubMed (original) (raw)
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons
Y Huang et al. Proc Natl Acad Sci U S A. 2001.
Abstract
Human apolipoprotein (apo) E4, a major risk factor for Alzheimer's disease (AD), occurs in amyloid plaques and neurofibrillary tangles (NFTs) in AD brains; however, its role in the pathogenesis of these lesions is unclear. Here we demonstrate that carboxyl-terminal-truncated forms of apoE, which occur in AD brains and cultured neurons, induce intracellular NFT-like inclusions in neurons. These cytosolic inclusions were composed of phosphorylated tau, phosphorylated neurofilaments of high molecular weight, and truncated apoE. Truncated apoE4, especially apoE4(Delta 272--299), induced inclusions in up to 75% of transfected neuronal cells, but not in transfected nonneuronal cells. ApoE4 was more susceptible to truncation than apoE3 and resulted in much greater intracellular inclusion formation. These results suggest that apoE4 preferentially undergoes intracellular processing, creating a bioactive fragment that interacts with cytoskeletal components and induces NFT-like inclusions containing phosphorylated tau and phosphorylated neurofilaments of high molecular weight in neurons.
Figures
Figure 1
Carboxyl-terminal-truncated forms of apoE accumulate in AD brains and NFTs. (a and b) Immunostaining of AD brain sections with anti-amino-terminal apoE (a) or anti-carboxyl-terminal apoE (b). (c and d) Double immunofluorescence staining of AD brain sections with anti-p-tau (red) and anti-amino-terminal apoE (green) (c) or anti-p-tau (red) and anti-carboxyl-terminal apoE (green) (d). (e and f) Neuro-2a cells expressing apoE3 or apoE4 were incubated with or without synthetic Aβ1–42 (10 μM) for 24 h at 37°C. After incubation, cell lysates were immunoprecipitated with a monospecific polyclonal anti-apoE followed by Western blotting with polyclonal anti-apoE (e) or monoclonal anti-apoE (6C5) (f) that recognizes the first 15 amino acids of the amino terminus of apoE (45). (g_–_k) Brain tissues from two nondemented normal individuals (N1 and N2) and three AD patients (AD1, AD2, and AD3) were homogenized. Both the supernatants (g and h) and the solubilized pellets (i_–_k) were subjected to SDS/PAGE and analyzed by Western blotting with polyclonal antibodies against full-length apoE (g and i), the carboxyl terminus (amino acids 272–299) of apoE (h and j), or a mAb against p-tau (AT8) (k). E Std, apoE standard (200 ng protein). (Original magnifications: a and b, ×200; c and d, ×600.)
Figure 2
Carboxyl-terminal-truncated apoE induces intracellular NFT-like inclusions in the cytosol of Neuro-2a cells. (a) Neuro-2a cells transiently transfected with apoE4 cDNA were double-immunostained with anti-apoE (green) and anti-p-tau (red) antibodies. This is representative of the cells containing apoE and p-tau immunoreactive intracellular inclusions (yellow) (more than 1,500 cells examined). (b) ApoE3- and apoE4-transfected Neuro-2a cells were incubated with or without 10 μM synthetic Aβ1–42 peptide at 37°C for 36 h. After incubation, the cells were double-immunostained with anti-apoE and anti-p-tau, and the percentage of transfected cells containing apoE and p-tau immunoreactive intracellular inclusions was calculated. Each column represents mean ± SD of four experiments (P < 0.001, apoE4 versus apoE3 or apoE4 + Aβ1–42 versus apoE3 + Aβ1–42; >400 transfected cells counted per experiment). (c) Cell lysates of apoE4-transfected Neuro-2a cells treated with Aβ1–42 (10 μM, 36 h) were immunoprecipitated with a monoclonal anti-p-tau (AT8 or AT270). Control lysates were not immunoprecipitated with anti-p-tau. Anti-apoE Western blotting revealed a band with a lower molecular mass than full-length apoE (≈29–30 kDa versus 34 kDa). (d) Neuro-2a cells were incubated for 30 h at 37°C with recombinant apoE4(Δ272–299) (30 μg/ml) complexed with rabbit β-very low density lipoproteins (20 μg of protein/ml). After incubation, the cells were fixed and immunostained for apoE. (e_–_h) Neuro-2a cells transiently transfected with apoE4(Δ272–299) (e_–_g) or apoE3(Δ272–299) (h) cDNA were double-immunostained with anti-apoE (e) and anti-p-tau (f) antibodies or immunostained with anti-apoE alone (h). (g) Merged image of e and f. (i_–_l) Neuro-2a cells were transiently transfected with DNA constructs encoding GFP (i), GFP-apoE3(Δ272–299) (j), or GFP-apoE4(Δ272–299) (k). All three constructs lacked the sequence encoding the signal peptide, resulting in direct expression of GFP-apoE in the cytosol. After transfection, the percentage of transfected cells containing intracellular filamentous inclusions was calculated (l) (mean ± SD of four experiments; >300 transfected cells counted per experiment. P < 0.001, GFP-apoE4(Δ272–299) versus GFP-apoE3(Δ272–299). (Original magnification: a and d_–_k, ×600.)
Figure 3
Electron micrograph of the intracellular inclusions induced by GFP-apoE4(Δ272–299) in Neuro-2a cells. Neuro-2a cells were transiently transfected with GFP (a) or GFP-apoE4(Δ272–299) (b and c). GFP-positive cells were sorted with a fluorescence-activated cell sorter, pelleted by centrifugation, and examined with a JEOL CCX-100II electron microscope. (Original magnifications: a and b, ×25,000; c, ×60,000.)
Figure 4
Intracellular inclusions induced by GFP-apoE4(Δ272–299) in Neuro-2a cells contain p-tau and p-NF-H. (a_–_f) Neuro-2a cells transiently transfected with GFP-apoE4(Δ272–299) were immunostained for p-tau (AT270; similar results were obtained with AT8) or p-NF-H (e, SM31; similar results were obtained with RT97) and imaged by confocal microscopy. (c) Merged image of a and b. (f) Merged image of d and e. (g_–_i) Detection of a complex containing p-tau (g), p-NF-H (h), and truncated apoE (i) in Neuro-2a cells transiently transfected with apoE4(Δ272–299) after immunoprecipitation with anti-apoE (g and h) or anti-p-tau (AT8) (i) and Western blotting. (Original magnification: a_–_f, ×600.)
Figure 5
The effects of deletions in the carboxyl- and amino-terminal domains of apoE on the formation of NFT-like structures in Neuro-2a cells. DNA constructs encoding fusion proteins of GFP and various carboxyl- or amino-terminal-truncated forms of apoE4 were prepared and transiently transfected into Neuro-2a cells. All constructs lacked the signal peptide sequence. (a) Model of apoE (modified from ref. 46) illustrating the structural regions where deletions were made and the polymorphic site (residue 112) that distinguishes apoE3 from apoE4. (b) Results defining amino acids 245–260 of apoE as critical for inclusion formation. (c) Deletion of helix 3 (amino acids 86–126) significantly reduced the ability of apoE4(Δ272–299) to form the intracellular inclusions (P < 0.001). The percentages of cells containing NFT-like structures were determined (mean ± SD of four experiments; >300 transfected cells counted per experiment).
Similar articles
- Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y. Brecht WJ, et al. J Neurosci. 2004 Mar 10;24(10):2527-34. doi: 10.1523/JNEUROSCI.4315-03.2004. J Neurosci. 2004. PMID: 15014128 Free PMC article. - Truncated apoE forms tangle-like structures in a neuronal cell line.
Ljungberg MC, Dayanandan R, Asuni A, Rupniak TH, Anderton BH, Lovestone S. Ljungberg MC, et al. Neuroreport. 2002 May 7;13(6):867-70. doi: 10.1097/00001756-200205070-00026. Neuroreport. 2002. PMID: 11997703 - Identification of an amino-terminal fragment of apolipoprotein E4 that localizes to neurofibrillary tangles of the Alzheimer's disease brain.
Rohn TT, Catlin LW, Coonse KG, Habig JW. Rohn TT, et al. Brain Res. 2012 Sep 26;1475:106-15. doi: 10.1016/j.brainres.2012.08.003. Epub 2012 Aug 8. Brain Res. 2012. PMID: 22902767 - Fragmentation of brain apolipoprotein E (ApoE) and its relevance in Alzheimer's disease.
Amponsah AE, Feng B, Guo R, Zhang W, He J, Kong D, Dong T, Ma J, Cui H. Amponsah AE, et al. Rev Neurosci. 2020 Aug 27;31(6):589-603. doi: 10.1515/revneuro-2019-0115. Rev Neurosci. 2020. PMID: 32364519 Review. - Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease.
Mahley RW, Nathan BP, Pitas RE. Mahley RW, et al. Ann N Y Acad Sci. 1996 Jan 17;777:139-45. doi: 10.1111/j.1749-6632.1996.tb34412.x. Ann N Y Acad Sci. 1996. PMID: 8624076 Review.
Cited by
- New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease.
Cao Y, Zhao LW, Chen ZX, Li SH. Cao Y, et al. Front Neurosci. 2024 Sep 11;18:1430465. doi: 10.3389/fnins.2024.1430465. eCollection 2024. Front Neurosci. 2024. PMID: 39323915 Free PMC article. Review. - Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy.
Qu L, Xu S, Lan Z, Fang S, Xu Y, Zhu X. Qu L, et al. Mol Neurobiol. 2024 Aug 31. doi: 10.1007/s12035-024-04449-1. Online ahead of print. Mol Neurobiol. 2024. PMID: 39214953 Review. - Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.
Faraji P, Kühn H, Ahmadian S. Faraji P, et al. J Mol Neurosci. 2024 Jul 3;74(3):62. doi: 10.1007/s12031-024-02224-4. J Mol Neurosci. 2024. PMID: 38958788 Free PMC article. Review. - Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
Ingannato A, Bagnoli S, Mazzeo S, Giacomucci G, Bessi V, Ferrari C, Sorbi S, Nacmias B. Ingannato A, et al. Front Endocrinol (Lausanne). 2024 Apr 9;15:1375302. doi: 10.3389/fendo.2024.1375302. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38654932 Free PMC article. - Cell type-specific roles of APOE4 in Alzheimer disease.
Blumenfeld J, Yip O, Kim MJ, Huang Y. Blumenfeld J, et al. Nat Rev Neurosci. 2024 Feb;25(2):91-110. doi: 10.1038/s41583-023-00776-9. Epub 2024 Jan 8. Nat Rev Neurosci. 2024. PMID: 38191720 Free PMC article. Review.
References
- Mahley R W. Science. 1988;240:622–630. - PubMed
- Mahley R W, Rall S C., Jr . In: The Metabolic and Molecular Bases of Inherited Disease. Scriver C R, Beaudet A L, Sly W S, Valle D, Childs B, Kinzler K W, Vogelstein B, editors. Vol. 2. New York: McGraw–Hill; 2001. pp. 2835–2862.
- Huang Y, Mahley R W. In: Plasma Lipids and Their Role in Disease. Barter P J, Rye K-A, editors. Amsterdam: Harwood; 1999. pp. 257–284.
- Roses A D. J Neuropathol Exp Neurol. 1994;53:429–437. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous